BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

12.73B

Market cap12.73B

Price-Earnings ratio

179.83

Price-Earnings ratio179.83

Dividend yield

—

Dividend yield—

Average volume

2.46M

Average volume2.46M

High today

$67.18

High today$67.18

Low today

$65.57

Low today$65.57

Open price

$66.69

Open price$66.69

Volume

241.02K

Volume241.02K

52 Week high

$70.98

52 Week high$70.98

52 Week low

$49.26

52 Week low$49.26

Stock Snapshot

With a market cap of 12.73B, BioMarin(BMRN) trades at $65.77. The stock has a price-to-earnings ratio of 179.83.

On 2026-08-24, BioMarin(BMRN) stock moved within a range of $65.57 to $67.18. With shares now at $65.77, the stock is trading +0.3% above its intraday low and -2.1% below the session's peak.

Trading volume for BioMarin(BMRN) stock has reached 241.02K, versus its average volume of 2.46M.

The stock's 52-week range extends from a low of $49.26 to a high of $70.98.

BMRN News

Simply Wall St 3d

BioMarin Pharmaceutical Beat Q2 Expectations, Is The Recent Re Rating Already Priced In?

BioMarin Pharmaceutical (BMRN) is back in focus after the company reported Q2 revenue that topped analyst expectations by 6.5% and issued full year EPS guidance...

TipRanks 5d

BioMarin Acquisition of Alesta Therapeutics Reinforces Growth Strategy; Whitney Ijem Reiterates Buy Rating and Maintains $114 Price Target

In a report released today, Whitney Ijem from Canaccord Genuity reiterated a Buy rating on BioMarin Pharmaceutical, with a price target of $114.00. Unlock powe...

TipRanks 6d

BMO starts BioMarin at Outperform, sees slower fade for Voxzogo

BMO Capital initiated coverage of BioMarin (BMRN) with an Outperform rating and $98 price target BioMarin is a profitable rare-disease company with durable enzy...

Analyst ratings

77%

of 30 ratings

Buy

76.7%

Hold

23.3%

Sell

More BMRN News

Investing.com 6d

Why is BioMarin Pharmaceutical stock surging today? - Investing.com

...

TipRanks 6d

BioMarin to Acquire Alesta Therapeutics, Expanding Skeletal Pipeline

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.